ACVR2B-AS1

Across TCGA pan-cancer cohorts, ACVR2B-AS1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ACVR2B-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where ACVR2B-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types ACVR2B-AS1 is over-expressed in tumor, although a few such as STAD and THCA show the opposite, repressed pattern.

STAD, THCA, and UCEC are the cancer types where ACVR2B-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACVR2B-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	All	−0.491	.003	7	view →
THCA	Female	All	−0.488	<.001	7	view →
UCEC	All	All	−1.255	<.001	6	view →
BRCA	Female	II,III,IV	−0.620	<.001	6	view →
KIRC	Male	II,III,IV	−0.482	<.001	5	view →
LIHC	All	All	+0.257	.002	4	view →
KICH	All	All	−0.586	.006	2	view →
PRAD	All	All	+0.352	<.001	2	view →
LUAD	All	II,III,IV	−0.273	.001	2	view →
BLCA	Male	IV	−1.077	.024	1	view →
COAD	All	All	+0.210	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ACVR2B-AS1–STAD

Open the STAD breakdown →